Form 4: Krystal Biotech Director Receives Stock Grant
Insider Transaction (Form 4)
Julian S Gangolli, a Director of Krystal Biotech, Inc., reported multiple transactions in common stock on September 14, 2026.
Summary
- Grant/award: acquired 1,187 Stock Option (Right to Buy) on September 14, 2026; holds 1,187 after (Direct).
- Grant/award: acquired 471 Restricted Stock Units on September 14, 2026; holds 471 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Julian S Gangolli — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-14 | Grant/award | Stock Option (Right to Buy) | 1,187 | — | — | 1,187 |
| 2026-09-14 | Grant/award | Restricted Stock Units | 471 | — | — | 471 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-14 | Grant/award (1,187 shares) |
| 2026-09-14 | Grant/award (471 shares) |
Keywords
insider transaction, Form 4, KRYS, Krystal Biotech, Inc., neutral, Julian S Gangolli
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.